BioNTech Cancer Drug Fails First Trial Endpoint
BioNTech said its BNT113 immunotherapy, combined with pembrolizumab, did not significantly improve progression-free survival at the first dual primary endpoint in a Phase 2/3 trial.
The company on Tuesday said the drug, in combination with pembrolizumab, didn't demonstrate a statistically significant improvement in prog…